Novel bladder cancer treatment gains MHRA approval in the UK

Johnson & Johnson has received marketing authorization for BALVERSA® (erdafitinib) as a treatment for adults with unresectable or metastatic urothelial carcinoma (UC) in the UK. This targeted therapy is for patients with fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have not responded to other treatments. The authorization is based on the positive results from the Phase 3 THOR study, showing erdafitinib significantly improved overall and progression-free survival compared to chemotherapy. The most common adverse reactions include hyperphosphatasemia, diarrhea, and stomatitis. Johnson & Johnson is committed to delivering innovative therapies for cancer patients and is working towards making erdafitinib available through the NHS.

Source link